about
Comparative investigation of respiratory tract involvement in granulomatosis with polyangiitis between PR3-ANCA positive and MPO-ANCA positive cases: a retrospective cohort study.Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study.Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.Clinical Features of Idiopathic Interstitial Pneumonia with Systemic Sclerosis-Related Autoantibody in Comparison with Interstitial Pneumonia with Systemic SclerosisSerum KL-6 and surfactant protein-D as monitoring and predictive markers of interstitial lung disease in patients with systemic sclerosis and mixed connective tissue disease.Isolated Brain Metastases as the First Relapse After the Curative Surgical Resection in Non-Small-Cell Lung Cancer Patients With an EGFR Mutation.Abundant immunoglobulin (Ig)G4-positive plasma cells in interstitial pneumonia without extrathoracic lesions of IgG4-related disease: is this finding specific to IgG4-related lung disease?Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study.A case of relapsed lung abscess caused by Eubacterium brachy infection following an initial diagnosis of pulmonary actinomycosis.Hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis: A single-center experience.Desquamative Interstitial Pneumonia Complicated with IgG4-related Lung Disease.A 16-year Follow-up Case of Interstitial Pneumonia with Systemic Sclerosis-rheumatoid Arthritis Overlap SyndromeClinical characteristics of pneumonia in bedridden patients receiving home care: a 3-year prospective observational study.Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis.Interstitial lung disease induced by alectinib (CH5424802/RO5424802).Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status.Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy?Unilateral Upper Lung Field Pulmonary Fibrosis Radiologically Consistent with Pleuroparenchymal Fibroelastosis after Thoracotomy: A New Disease Entity Related to Thoracotomy.Diffuse alveolar hemorrhage as a fatal adverse effect of bevacizumab: an autopsy case.Retroperitoneal Metastasis from Lung Adenocarcinoma Mimics Retroperitoneal Fibrosis.Identifying the Cause of the "Saturation Gap": Two Cases of Dapsone-induced Methemoglobinemia.Chronological assessment of airway lesions in relapsing polychondritis by positron emission tomography.Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: ThorASP8273 tolerability and antitumor activity in TKI-naive Japanese patients with EGFR mutation-positive non-small cell lung cancer.Secondary pulmonary alveolar proteinosis predominant in the transplanted lung in patients with idiopathic interstitial pneumonia: an autopsy case.Pulmonary follicular lymphoma showing diffuse micronodules mimicking sarcoidosisNegative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosisRapid effect of osimertinib re-challenge on brain metastases developing during salvage cytotoxic chemotherapy after osimertinib treatment failure: A case reportMiliary lung metastases from non-small cell lung cancer with Exon 20 insertion: A dismal prognostic entity: A case report.[A case of pulmonary Mycobacterium gordonae infection diagnosed by gastric juice culture and successfully treated with multidrug chemotherapy]Prognostic factors and disease behaviour of pathologically proven fibrotic non-specific interstitial pneumoniaPredictive Factors for the Long-Term Deterioration of Pulmonary Function in Interstitial Lung Disease Associated with Anti-Aminoacyl-tRNA Synthetase AntibodiesEvaluation of changes in the serum levels of Krebs von den Lungen-6 and surfactant protein-D over time as important biomarkers in idiopathic fibrotic nonspecific interstitial pneumoniaLow starting-dosage of nintedanib for the reduction of early terminationSummary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumoniaPemetrexed-induced Interstitial Lung Disease Mimicking Hypersensitivity Pneumonia: A Pathologically Proven CaseA Phase II Study of Cisplatin Plus Gemcitabine followed by Maintenance Gemcitabine for Advanced Squamous Non-Small-Cell Lung Cancer: Kyoto Thoracic Oncology Research Group 1302Erdheim-Chester disease progression from miliary pulmonary nodules to large tumoursA phase II study of atezolizumab for pretreated advanced/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936/AMBITIOUS study
P50
Q35724221-CEEAD2AF-EBB9-4A4B-B108-76E0D5FA6EBBQ35761863-11EBC9F5-53CA-41F8-B581-E0B67044E3E1Q35864644-1ED34A87-6C66-4AFF-910E-0AEC16D77C53Q35945391-095CC880-BA5D-4364-B581-626C833B5D58Q36114308-1D3C24DD-F162-45C1-941D-91CBAEF06F27Q37677616-417DCB15-4DD9-4587-9C70-EDD4D983D69FQ39409981-5B9F9FD5-1230-42B7-977B-7EBF09D1D8FCQ39531708-9D3C5944-8EB8-4E06-8BC5-8A367AB4C981Q39808352-65A11102-1AF5-45F6-8027-5B361BE71C75Q40073732-9E012ECE-7188-45E7-96C2-BE761D37EDABQ40408997-B4EDA21B-CECF-4E3D-AA6B-58F49645BDF5Q40985535-EE2B9C2B-E28C-403A-BAB4-ABF2AFFCC750Q40985543-6E97281B-7DB4-46FA-AFA0-E4BE0DA648FBQ41194769-02D72604-3726-48BC-9BC3-48C4C568B7BCQ41545729-7E1B4F78-2551-456C-887F-47EB724963E0Q41660655-896F9A11-8755-4A62-B382-020121BBD58CQ47119173-9B15B168-8128-4AC6-98F7-CE4A1DF7CC98Q47643636-6A8F696B-984A-4722-918C-281783072FFAQ47787332-A92D507A-BEA7-4514-BA1D-74FEA1021B5CQ51150156-32ED5860-AAF5-4ED8-8311-A2ED7CF92EE5Q51560604-4D9817ED-8199-4F73-8FD5-963C5F5F5BD0Q51616492-F90C9F29-1172-41CA-84B4-15772BDBC893Q51633566-76A9CF2E-3C14-4682-BFA9-4F7DD2C33F1CQ52676775-E5356F10-9387-4FB9-89ED-6C75EB162281Q54977912-71CEBE77-F165-4C65-A1BC-BE67608F4C9CQ55602066-55B6DF33-B1BC-4371-AADA-6A3B10E0E794Q58544545-B622CF29-99E5-4571-9B31-1A485DCF854EQ64053794-2032E96D-D246-478D-9390-CC2DC31E9973Q64096504-399930FB-FE62-46EB-A846-230BF3623943Q64936082-0DA2961C-CEB4-4FDE-AFD6-6686B4D1525AQ86024847-EB836C81-BB2F-457A-A3DE-C0D600C2B543Q88468166-2FD73062-BBD6-4E48-94CD-DE8E8FD1D1D6Q88693866-D0480096-9270-49B7-9CF1-D0DE95FC1B43Q90024012-22792CF5-D577-4C03-BF06-8FBFC3943435Q91648064-9BFBD6D4-EFE9-43E6-AF86-00524D9E2D18Q92385752-4970A24D-9D0E-43F9-BC6F-40DF843C1B7AQ92616110-F8BB4B43-7C33-40CA-906C-5213C7056DF5Q92618120-E845EF2C-3AB4-4127-A156-3735257D4657Q92968076-DD976236-9259-4B18-B1AE-FB1AA4CDA4D3Q95273189-E76ACC67-242B-4821-B3C1-706A24D2BA25
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Satoshi Ikeda
@ast
Satoshi Ikeda
@en
Satoshi Ikeda
@es
Satoshi Ikeda
@nl
Satoshi Ikeda
@sl
type
label
Satoshi Ikeda
@ast
Satoshi Ikeda
@en
Satoshi Ikeda
@es
Satoshi Ikeda
@nl
Satoshi Ikeda
@sl
prefLabel
Satoshi Ikeda
@ast
Satoshi Ikeda
@en
Satoshi Ikeda
@es
Satoshi Ikeda
@nl
Satoshi Ikeda
@sl
P1053
P-3144-2015
P106
P1153
56201698900
P1960
zl3N2HYAAAAJ
P21
P31
P3829
P496
0000-0001-5203-7911